Olema Pharmaceuticals, Inc.
OLMA
$5.59
-$0.17-2.95%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 17.08M | 17.53M | 17.74M | 18.82M | 18.31M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 147.13M | 142.79M | 137.26M | 133.71M | 119.43M |
Operating Income | -147.13M | -142.79M | -137.26M | -133.71M | -119.43M |
Income Before Tax | -142.30M | -128.89M | -129.47M | -122.68M | -109.63M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -142.30 | -128.89 | -129.47 | -122.68 | -109.63 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -142.30M | -128.89M | -129.47M | -122.68M | -109.63M |
EBIT | -147.13M | -142.79M | -137.26M | -133.71M | -119.43M |
EBITDA | -146.66M | -142.36M | -136.87M | -133.34M | -119.07M |
EPS Basic | -1.98 | -2.01 | -2.21 | -2.19 | -2.06 |
Normalized Basic EPS | -1.17 | -1.26 | -1.33 | -1.34 | -1.27 |
EPS Diluted | -1.98 | -2.01 | -2.21 | -2.19 | -2.06 |
Normalized Diluted EPS | -1.17 | -1.26 | -1.33 | -1.34 | -1.27 |
Average Basic Shares Outstanding | 293.98M | 264.76M | 234.91M | 223.90M | 211.62M |
Average Diluted Shares Outstanding | 293.98M | 264.76M | 234.91M | 223.90M | 211.62M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |